Amplify study apixaban

Oral Apixaban for the Treatment of Acute Venous ...

★ ★ ★ ★ ☆

Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. Methods In this randomized, double-blind study, we compared ...

Oral Apixaban for the Treatment of Acute Venous ...

Apixaban for Extended Treatment of Venous Thromboembolism

★ ★ ☆ ☆ ☆

Study Design and Oversight. We conducted a randomized, double-blind study comparing the efficacy and safety of two doses of apixaban with those of placebo for the extended treatment of venous ...

Apixaban for Extended Treatment of Venous Thromboembolism

The AMPLIFY trial: Apixaban for treatment of venous ...

★ ★ ☆ ☆ ☆

The purpose of the Apixiban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial was to determine if apixaban, an oral factor Xa inhibitor, would be non-inferior to conventional therapy (i.e., enoxaparin followed by warfarin) for the treatment of acute venous thromboembolic disease.

The AMPLIFY trial: Apixaban for treatment of venous ...

AMPLIFY Clinical Trial | DVT & PE Patients | Eliquis UK

★ ★ ★ ★ ★

In AMPLIFY, ELIQUIS (apixaban) demonstrated comparable efficacy with significantly fewer major bleeding events vs. enoxaparin / warfarin in patients receiving treatment for DVT / PE 1 Study design * Efficacy analyses based on ITT population for whom the outcome status at 6 months was documented.

AMPLIFY Clinical Trial | DVT & PE Patients | Eliquis UK

Oral apixaban for the treatment of venous thromboembolism ...

★ ★ ★ ★ ★

BACKGROUND: The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE). OBJECTIVE: To perform a subgroup analysis to compare the efficacy and safety of apixaban and enoxaparin followed by warfarin for the treatment of VTE in patients with cancer enrolled in AMPLIFY.

Oral apixaban for the treatment of venous thromboembolism ...

Apixaban - PubMed Central (PMC)

★ ★ ☆ ☆ ☆

5/29/2013 · Indications. Apixaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1 The US Food and Drug Administration (FDA)–approved indications for rivaroxaban, dabigatran, and warfarin are compared in Table 1.

Apixaban - PubMed Central (PMC)

Oral apixaban for the treatment of venous thromboembolism ...

★ ★ ★ ★ ☆

9/26/2015 · In the AMPLIFY study on VTE treatment, apixaban was shown to be non‐inferior to enoxaparin followed by warfarin, and produced significantly less bleeding 3. Using data from this study, we performed a subgroup analysis to compare the efficacy and safety of apixaban and enoxaparin followed by warfarin in patients with active cancer or a history ...

Oral apixaban for the treatment of venous thromboembolism ...

Common Side Effects of Eliquis (Apixaban Tablets ... - RxList

★ ★ ★ ★ ★

2/26/2018 · AMPLIFY Study. The mean duration of exposure to ELIQUIS was 154 days and to enoxaparin/warfarin was 152 days in the AMPLIFY study. Adverse reactions related to bleeding occurred in 417 (15.6%) ELIQUIS-treated patients compared to 661 (24.6%) enoxaparin/warfarin-treated patients.

Common Side Effects of Eliquis (Apixaban Tablets ... - RxList

Apixaban - an overview | ScienceDirect Topics

★ ★ ★ ★ ☆

Apixaban was less effective than the comparators, but there were significant and similar dose-related increases in the incidence of total bleeding events with once- and twice-daily apixaban. In a dose-ranging study 520 patients with deep vein thrombosis were randomized to apixaban 5 mg bd, 10 mg bd, or 20 mg/day, or to low-molecular-weight ...

Apixaban - an overview | ScienceDirect Topics

Bristol-Myers Squibb and Pfizer to Present New Data on ...

★ ★ ★ ☆ ☆

8/20/2014 · Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014 . Fourteen abstracts to be presented, including new analyses from the ARISTOTLE ®, AMPLIFY ® and AMPLIFY-EXT ...

Bristol-Myers Squibb and Pfizer to Present New Data on ...

Apixaban for the Treatment of Japanese Subjects With Acute ...

★ ★ ★ ★ ☆

In the multi-regional AMPLIFY study, a fixed-dose regimen of apixaban alone was non-inferior to conventional therapy for treatment of PE/DVT and was associated with significantly fewer bleeding ...

Apixaban for the Treatment of Japanese Subjects With Acute ...

Efficacy and Safety Study of Apixaban for the Treatment of ...

★ ★ ☆ ☆ ☆

3/26/2008 · Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Efficacy and Safety Study of Apixaban for the Treatment of ...

Oral apixaban for the treatment of venous thromboembolism ...

★ ★ ★ ★ ★

9/26/2015 · The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE). Objective To perform a subgroup analysis to compare the efficacy and safety of apixaban and enoxaparin followed by warfarin for the treatment of VTE in patients with cancer enrolled in AMPLIFY.

Oral apixaban for the treatment of venous thromboembolism ...

A Phase III Study of Apixaban in Patients With Atrial ...

★ ★ ★ ★ ☆

7/4/2007 · A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES) ... The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with …

A Phase III Study of Apixaban in Patients With Atrial ...

Bristol-Myers Squibb and Pfizer Initiate New Study in the ...

★ ★ ★ ★ ★

The AMPLIFY (Apixaban after the initial Management of Pulmonary embolism and deep vein thrombosis with First-line therapy) trials are part of the EXPANSE program - the global Phase 3 clinical development trial program for apixaban. AMPLIFY and AMPLIFY-EXT are two major clinical trials involving approximately 7,300 patients with deep vein ...

Bristol-Myers Squibb and Pfizer Initiate New Study in the ...

The ARISTOTLE trial: Apixaban vs warfarin in atrial ...

★ ★ ★ ★ ★

Study Rundown: Warfarin is a vitamin K antagonist that has long been the mainstay of anticoagulation therapy for prevention of thromboembolic stroke in patients with atrial fibrillation. Recently, apixiban, a direct Xa inhibitor, was introduced to the market. It has a much wider therapeutic range ...

The ARISTOTLE trial: Apixaban vs warfarin in atrial ...

DailyMed - ELIQUIS- apixaban tablet, film coated ELIQUIS ...

★ ★ ★ ☆ ☆

6/28/2018 · Approximately one-third of patients participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study. A total of 2482 patients were randomized to study treatment and were followed for a mean of approximately 330 days in the ELIQUIS group and 312 days in the placebo group. The mean age in the AMPLIFY-EXT study was 57 years.

DailyMed - ELIQUIS- apixaban tablet, film coated ELIQUIS ...

Clarification for Apixaban Dosing in Patients with ...

★ ★ ★ ★ ★

To our knowledge, the only clinical trial that addresses the question of apixaban use for venous thromboembolism in patients with impaired renal function is the AMPLIFY study.3 Patients were ...

Clarification for Apixaban Dosing in Patients with ...

For Patients with Cancer and VTE, Apixaban Associated with ...

★ ★ ★ ☆ ☆

3/1/2016 · Using data from the randomized, double-blind AMPLIFY study that compared apixaban and enoxaparin followed by warfarin in patients with cancer and VTE, Giancarlo Agnelli, MD, from the University of Perugia in Italy, and colleagues conducted a subgroup analysis in patients with active cancer or a history of cancer at study inclusion.

For Patients with Cancer and VTE, Apixaban Associated with ...

Oral Anticoagulant | Rx ELIQUIS® (apixaban) | Safety Info

★ ★ ★ ★ ★

The anticoagulant effect of apixaban can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). An agent to reverse the anti-factor Xa activity of apixaban is available. Please visit www.andexxa.com for more information on availability of a reversal agent.

Oral Anticoagulant | Rx ELIQUIS® (apixaban) | Safety Info

Apixaban: AMPLIFY Study Design - Clinical Trials of Oral ...

★ ★ ★ ★ ☆

Turning to the AMPLIFY study with apixaban, a total of 4816 patients with DVT or PE were enrolled into a single study (Figure 13). [11] The comparator was the classic therapy of enoxaparin followed by a vitamin K antagonist. AMPLIFY was a double-blind trial, very similar to the EINSTEIN studies in that it employed the same single-drug approach.

Apixaban: AMPLIFY Study Design - Clinical Trials of Oral ...

Apixaban AMPLIFY Trial Flashcards | Quizlet

★ ★ ★ ★ ★

Start studying Apixaban AMPLIFY Trial. Learn vocabulary, terms, and more with flashcards, games, and other study tools.

Apixaban AMPLIFY Trial Flashcards | Quizlet

Apixaban appears safe, effective for patients with cancer, VTE

★ ★ ★ ☆ ☆

5/10/2016 · Apixaban appeared to serve as a feasible management option for patients with cancer and venous thromboembolism, according to the results of a subgroup analysis from the …

Apixaban appears safe, effective for patients with cancer, VTE
Uil-mathematics-study-guide.html,Uiuc-programs-of-study.html,Uja-ny-jewish-population-study.html,Uk-biobank-pilot-study-meaning.html,Uk-study-abroad-tips-england.html